JP2002518011A5 - - Google Patents

Download PDF

Info

Publication number
JP2002518011A5
JP2002518011A5 JP2000554853A JP2000554853A JP2002518011A5 JP 2002518011 A5 JP2002518011 A5 JP 2002518011A5 JP 2000554853 A JP2000554853 A JP 2000554853A JP 2000554853 A JP2000554853 A JP 2000554853A JP 2002518011 A5 JP2002518011 A5 JP 2002518011A5
Authority
JP
Japan
Prior art keywords
bpi
analog
host cell
deleted
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000554853A
Other languages
English (en)
Other versions
JP2002518011A (ja
Filing date
Publication date
Priority claimed from US09/099,725 external-priority patent/US6013631A/en
Application filed filed Critical
Publication of JP2002518011A publication Critical patent/JP2002518011A/ja
Publication of JP2002518011A5 publication Critical patent/JP2002518011A5/ja
Pending legal-status Critical Current

Links

Description

【特許請求の範囲】
【請求項１】 成熟ヒトＢＰＩのアミノ酸残基１０〜１９３からなり、ここで、１３２位のシステイン残基は、異なるアミノ酸で置換されている、殺菌性／透過性増加タンパク質（ＢＰＩ）欠失アナログ。
【請求項２】 前記システイン残基を置換する前記アミノ酸が、アラニンおよびセリンからなる群より選択される非極性アミノ酸である、請求項１に記載のＢＰＩ欠失アナログ。
【請求項３】 前記１３２位のシステイン残基が、アラニンで置換される、請求項１に記載のＢＰＩ欠失アナログ。
【請求項４】 請求項１に記載のＢＰＩ欠失アナログをコードするポリヌクレオチド。
【請求項５】 請求項３に記載のＢＰＩ欠失アナログをコードするポリヌクレオチド。
【請求項６】 ＢＰＩの２７アミノ酸のリーダー配列をさらに含む、請求項４に記載のポリヌクレオチド。
【請求項７】 ＤＮＡである、請求項４に記載のポリヌクレオチド。
【請求項８】 請求項７に記載のＤＮＡを含む発現ベクター。
【請求項９】 宿主細胞において前記ポリペプチド欠失アナログの発現を可能にする様式で、請求項７に記載のＤＮＡによって安定に形質転換またはトランスフェクトされた宿主細胞。
【請求項１０】 請求項９に従う、真核生物宿主細胞。
【請求項１１】 ＣＨＯ細胞である、請求項１０の宿主細胞。
【請求項１２】 ＢＰＩ欠失アナログポリペプチドを産生するための方法であって、該方法は、請求項９に記載の宿主細胞を適切な培養培地中で増殖させる工程、および該宿主細胞または該培養培地から該ポリペプチドを単離する工程を包含する、方法。
【請求項１３】 請求項１２に記載の方法のポリペプチド産物。
【請求項１４】 請求項１に記載のＢＰＩ欠失アナログおよび薬学的に受容可能な賦形薬、アジュバント、またはキャリアを含む組成物。
【請求項１５】 請求項３に記載のＢＰＩ欠失アナログおよび薬学的に受容可能な賦形薬、アジュバント、またはキャリアを含む組成物。
【請求項１６】 請求項１３に記載のＢＰＩ欠失アナログおよび薬学的に受容可能な賦形薬、アジュバント、またはキャリアを含む組成物。
【請求項１７】 被験体への投与に適切な医薬の製造のための、請求項１４に記載の組成物の使用。
【請求項１８】 被験体への投与に適切な医薬の製造のための、請求項１５に記載の組成物の使用。
【請求項１９】 被験体への投与に適切な医薬の製造のための、請求項１６に記載の組成物の使用。
JP2000554853A 1998-06-19 1999-06-18 殺菌性／透過性増加タンパク質（ｂｐｉ）欠失アナログ Pending JP2002518011A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/099,725 US6013631A (en) 1998-06-19 1998-06-19 Bactericidal/permeability-increasing protein (BPI) deletion analogs
US09/099,725 1998-06-19
PCT/US1999/013860 WO1999066044A1 (en) 1998-06-19 1999-06-18 Bactericidal/permeability-increasing protein (bpi) deletion analogs

Publications (2)

Publication Number Publication Date
JP2002518011A JP2002518011A (ja) 2002-06-25
JP2002518011A5 true JP2002518011A5 (ja) 2006-06-29

Family

ID=22276330

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000554853A Pending JP2002518011A (ja) 1998-06-19 1999-06-18 殺菌性／透過性増加タンパク質（ｂｐｉ）欠失アナログ

Country Status (9)

Country Link
US (4) US6013631A (ja)
EP (1) EP1086230A1 (ja)
JP (1) JP2002518011A (ja)
CN (1) CN1273598C (ja)
AU (1) AU755624B2 (ja)
CA (1) CA2331880A1 (ja)
MX (1) MXPA00011398A (ja)
NZ (1) NZ508816A (ja)
WO (1) WO1999066044A1 (ja)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
WO2000071149A2 (en) * 1999-05-24 2000-11-30 Xoma (Us) Llc Therapeutic uses of bpi protein products in humans with otitis media with effusion
US20020173464A1 (en) * 2000-12-01 2002-11-21 King George L. Modulation of pericyte proliferation
DE60335794D1 (de) 2002-03-29 2011-03-03 Xoma Technology Ltd Multigene vectoren und methoden für eine erhöhte expression von rekombinanten polypeptiden
US8765124B2 (en) 2003-02-28 2014-07-01 Chugai Seiyaku Kabushiki Kaisha Stabilized preparation containing protein
EP1891207A2 (en) * 2005-06-03 2008-02-27 Biovitrum AB Process for cultivating animal cells comprising the feeding of plant-derived peptones
EP1741440A1 (en) 2005-07-08 2007-01-10 Mellitus S.L. Use of BPI protein for the treatment of disorders of the metabolism and cardiovascular disorders
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
EP2139509A2 (en) * 2007-03-15 2010-01-06 Biogen Idec MA, Inc. Treatment of autoimmune disorders
CN103648515B (zh) 2011-04-05 2018-01-02 达纳-法伯癌症研究所有限公司 作为辐射缓和剂和辐射防护剂的bpi和其同源物
GB201319621D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
GB201319620D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
KR102270048B1 (ko) * 2020-07-10 2021-06-28 주식회사 녹십자 바리셀라 조스터 바이러스 표면 단백질 항원의 생산 방법
CN115947868A (zh) * 2022-09-28 2023-04-11 安君(北京)基因科技有限责任公司 Cxcl-bpi融合蛋白及其用途

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5576292A (en) * 1987-08-11 1996-11-19 New York University Biologically active bactericidal/permeability-increasing protein fragments
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
WO1994025476A1 (en) * 1993-04-30 1994-11-10 Incyte Pharmaceuticals, Inc. Recombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
US5308834A (en) * 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
US5770694A (en) * 1990-08-13 1998-06-23 Incyte Pharmaceuticals, Inc. Genetically engineered BPI variant proteins
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
DE69128968T2 (de) * 1990-12-03 1998-10-08 Univ New York Biologisch aktive bakterizide/permeabilitätserhöhende proteinbruchstücke
WO1993006228A1 (en) * 1991-09-26 1993-04-01 Incyte Pharmaceuticals, Inc. A new form of liposaccharide binding protein (lbp)
JP3391453B2 (ja) * 1992-05-19 2003-03-31 ゾーマ コーポレイション 内毒素結合タンパク質の調製のための方法
US5643570A (en) * 1992-05-19 1997-07-01 Xoma Corporation BPI-immunoglobulin fusion proteins
DK0682524T3 (da) * 1993-02-02 2002-01-28 Xoma Technology Ltd Farmaceutiske præparater indeholdende et baktericid/permeabilitetsforøgende protein og et afspændingsmiddel
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
WO1994019323A1 (en) 1993-02-18 1994-09-01 Merck Sharp & Dohme Limited Azacyclic compounds, compositions containing them and their use as tachykinin antagonists
ATE169304T1 (de) * 1993-03-12 1998-08-15 Xoma Corp Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung
US5733872A (en) * 1993-03-12 1998-03-31 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
DE69410254T2 (de) * 1993-03-12 1998-12-17 Xoma Corp., Berkeley, Calif. Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
MX9401807A (es) * 1993-03-12 1995-01-31 Xoma Corp Usos terapeuticos de productos de proteina que incrementan lapermeabilidad/bactericidas.
WO1994021280A1 (en) * 1993-03-22 1994-09-29 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein and lipopolysaccharide binding protein levels and ratios thereof in diagnosis
US5731415A (en) * 1993-06-17 1998-03-24 Xoma Corporation Lipopolysaccharide binding protein derivatives
ATE229980T1 (de) * 1993-07-02 2003-01-15 Incyte Pharma Inc Glycosilierte und nichtglycolisierte bakterizide/die permeabilität erhoehende proteine und methoden zu ihrer herstellung
US5770561A (en) * 1993-07-14 1998-06-23 Xoma Corporation Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
WO1995002414A1 (en) * 1993-07-14 1995-01-26 Xoma Corporation Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
US5466580A (en) * 1993-09-22 1995-11-14 Xoma Corporation Method for quantifying BPI in body fluids
JPH09502987A (ja) * 1993-09-22 1997-03-25 ゾーマ コーポレイション 殺菌性／浸透性が向上した（ｂｐｉ）タンパク質生成物および抗生物質の投与によるグラム陰性細菌感染の治療方法
CN1133634A (zh) * 1993-09-22 1996-10-16 爱克斯欧玛公司 定量体液中的bpi的方法
ZA947783B (en) * 1993-10-15 1996-05-05 Xoma Corp Method of treating depressed reticuloendothelial system function
MX9602570A (es) * 1994-01-14 1997-04-30 Xoma Corp Metodos y materiales anti-fungosos.
PT754050E (pt) * 1994-01-14 2002-11-29 Xoma Technology Ltd Metodos e materiais contra bacterias gram-positivas
US5643875A (en) * 1994-01-24 1997-07-01 Friedmann; Nadav Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products
US5484705A (en) * 1994-01-24 1996-01-16 Xoma Corporation Method for quantifying lipopolysaccharide binding protein
US5447913A (en) * 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5786324A (en) * 1994-03-24 1998-07-28 Regents Of The University Of Minnesota Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5578568A (en) * 1994-04-22 1996-11-26 Xoma Corporation Method of treating conditions associated with intestinal ischemia/reperfusion
US5532216A (en) * 1994-06-24 1996-07-02 Incyte Pharmaceuticals, Inc. Neutralization of non-lipopolysaccharide compounds by bactericidal/permeability-increasing protein
US5646114A (en) * 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
WO1996008509A1 (en) * 1994-09-15 1996-03-21 Xoma Corporation Anti-fungal peptides
US5912228A (en) * 1995-01-13 1999-06-15 Xoma Corporation Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
US5494896A (en) * 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries
CA2227292A1 (en) * 1995-07-20 1997-02-06 Xoma Corporation Anti-fungal peptides
JP2000501386A (ja) * 1995-11-14 2000-02-08 ゾーマ コーポレイション 角膜損傷に関連する病態を処置するための、殺菌性／透過性増強（ｂｐｉ）タンパク質
US5686414A (en) * 1995-11-14 1997-11-11 Xoma Corporation Methods of treating conditions associated with corneal transplantation
DK0914144T3 (da) * 1996-05-10 2001-04-09 Univ Texas Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
ATE234111T1 (de) * 1996-05-23 2003-03-15 Xoma Technology Ltd Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
WO1998019694A1 (en) * 1996-11-01 1998-05-14 Xoma Corporation Therapeutic uses of bpi protein products in cystic fibrosis patients
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs

Similar Documents

Publication Publication Date Title
JP2002518011A5 (ja)
JP2003530839A5 (ja)
JP2004501618A5 (ja)
CA2155004A1 (en) Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same
CA2230885A1 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
KR890003802A (ko) 재조합 dna 기술에 의해 제조된 소의 췌장 트립신 억제제, 그 제조 방법, 발현 벡터 및 재조합 숙주 및 그의 제약적 용도
HRP20170755T1 (hr) Rekombinantni proteini elastaze i postupci proizvodnje i uporabe istih
MY123371A (en) Protein for blocking platelet adhesion
ES2279510T3 (es) Generacion de insulina humana.
DE60329201D1 (de) Substituierte wt1-peptide
CA2227516A1 (en) Acylated oligopeptide derivatives having cell signal inhibiting activity
WO2004022003A3 (en) Materials and methods for treatment of allergic diseases
KR880009125A (ko) 재조합 숙주에 의해 제조되는 췌장분비 트립신 억제제 및 그의 변이체, 그의 방법, 표현벡터 및 재조합 숙주 및 그의 제약상 용도
DK170346B1 (da) Granulocyt-makrofag-"Colony Stimulating"-faktor(CSF)-proteiner, fremgangsmåde til fremstilling deraf, ekspressionsvektor og E.coli-celle til brug ved denne fremgangsmåde samt anvendelse af disse proteiner
JP2004531242A5 (ja)
WO2000034474A3 (en) Growth factor homolog zvegf3
JP2006518331A5 (ja)
HU0000992D0 (en) Genetically engineered cell culture adapted infections bursal diseases virus (ibdv)mutants
HRP20100340T1 (hr) Polipeptidi koji imaju antimikrobno djelovanje i polinukleotidi koji ih kodiraju
JP2005519591A (ja) 毛包成長
CN100469779C (zh) 白细胞介素-1β转化酶抑制剂
NZ508816A (en) Bactericidal/permeability-increasing protein (BPI) deletion analogs
EP1209226A3 (en) Maturation of dendritic cells by recombinant heat shock protein 70 (hsp70)
CA2011008C (en) Egf variants and pharmaceutical use thereof
JP2008518622A5 (ja)